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Antineutrophil cytoplasmic autoantibodies (ANCA) are
associated with necrotizing crescentic glomerulonephritis
(NCGN) and systemic vasculitis. We examined the role of
phosphoinositol 3 kinase-c isoform (PI3Kc) in ANCA-activated
neutrophil functions. Further, we tested whether its
inhibition protects a mouse model of ANCA NCGN from
developing NCGN. We transplanted bone marrow from
wild-type mice or PI3Kc-deficient mice into myeloperoxidase-
deficient mice immunized with myeloperoxidase. Bone
marrow from PI3Kc/ mice protected against development
of the disease. Similarly, bone marrow transplanted from
wild-type mice followed by treatment with the specific
PI3Kc inhibitor AS605240 also protected these mice against
NCGN in this model. AS605240 significantly abrogated
myeloperoxidase- or proteinase 3-ANCA-stimulated
superoxide production in vitro. Furthermore, ANCA-induced
degranulation and GM-CSF-stimulated migration in a
transwell assay of isolated human neutrophils were also
abrogated by the drug. We found that PI3Kc plays a pivotal
role in ANCA-induced NCGN and suggest that its specific
inhibition may provide a novel treatment target.
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Patients with necrotizing crescentic glomerulonephritis
(NCGN) and systemic small-vessel vasculitis feature antineu-
trophil cytoplasmic autoantibodies (ANCAs).1,2 ANCAs
activate neutrophils and are pathogenic in a mouse model.3–9
ANCAs bind to ANCA antigens on the cell membrane of
cytokine-primed neutrophils.10–12 Signaling pathways are
activated that mediate several functions.3,6,11,13–20 The phos-
phoinositol 3-kinase (PI3K)/Akt pathway is pivotal for
ANCA-induced respiratory burst activity.13,15,21 The PI3K
family is divided into four classes, namely, IA, IB, II, and III.
22
Class I is responsible for cell-surface-receptor-generated
phosphatidylinositol 3,4,5-bisphosphate that regulates the
nicotinamide adenine dinucleotide phosphate oxidase.23 Class
I PI3K consists of a regulatory and one of three different p110
catalytic subunits. Two class I subclasses are distinguished,
namely, IA and IB. IA enzymes have three types of p110
catalytic subunits: p110a and p110b, which are expressed
in many tissues, whereas p110d is expressed primarily in
leukocytes. The single IB enzyme, p110g, is expressed
preferentially in leukocytes. IA enzymes are activated by
protein tyrosine kinase receptors, whereas IB enzyme is
activated through G-protein-coupled receptors. PI3Kg con-
trols neutrophil respiratory burst, migration, and Akt
activation in response to various ligands and in vitro
experiments by Ben-Smith et al.13,24–30 implicated the
g-isoform also in ANCA-mediated neutrophil activation. All
of these functions participate in ANCA-mediated organ
damage. Recently, the small-molecule PI3Kg inhibitor AS605240
with more than 30-fold selectivity over PI3Kd and PI3Kb and
7.5-fold selectivity over PI3Ka was generated. AS605240
(1 mmol/l) blocked PI3Kg-dependent Akt phosphorylation
in primary monocytes, whereas PI3Kg-independent Akt
phosphorylation was not affected.28 Furthermore, specific
PI3Kg inhibition blocked glomerulonephritis and improved
survival in a lupus erythematosus mouse model.31 AS605240
is orally active and 50 mg/kg twice a day suppressed
rheumatoid arthritis in another mouse model.28 We tested
whether the PI3Kg isoform controls neutrophil functions
that mediate ANCA-induced NCGN. We found that PI3Kg
could be a treatment target for ANCA-induced NCGN.
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RESULTS
Bone marrow from PI3Kc-deficient animals provides
protection from ANCA-induced NCGN
We first tested the hypothesis that PI3Kg has an important
function in an ANCA-glomerulonephritis mouse model.
Anti-myeloperoxidase (MPO)-mediated NCGN was induced
by the previously described bone marrow (BM) transplanta-
tion approach.32,33 MPO-deficient animals were immunized
with MPO, irradiated, and transplanted with BM cells from
either wild-type (WT) mice or PI3Kg gene-deficient
(PI3Kg/) animals (n¼ 8 in each group). At 8 weeks after
transplantation, mice were killed. All mice (100%) trans-
planted with WT BM developed hematuria and proteinuria,
whereas mice transplanted with PI3Kg/ BM did not
develop significant urine abnormalities. These results were
confirmed by a higher urinary albumin excretion in the mice
transplanted with WT BM compared with the PI3Kg/ BM
group (1047.0±783.5 mg/ml albumin in the WT mice versus
203.9±67.4 mg/ml in the PI3Kg/ mice). The values did not
reach statistical significance because of high interindividual
variability.
All mice transplanted with WT BM developed NCGN on
histology (100% disease induction) whereas in the PI3Kg/
BM group mice developed only weak glomerular abnormal-
ities (six of the eight mice got weak glomerular disease, two
did not develop any glomerular abnormalities). When these
findings were quantitatively assessed, mice in the WT BM
group showed on average 22.3±7.5% crescents and
9.7±2.8% necrosis whereas mice in the PI3Kg/ BM group
developed 3.1±1.1% crescents and 2.5±0.3% necrosis
(Po0.05 for both) (Figure 1). Immunohistology showed
weak IgG, IgA, IgM, and C3 deposition that did not differ
between both groups (data not shown). By enzyme-linked
immunosorbent assay we found similar anti-MPO titer in
both experimental groups (WT group: d0 1.25±0.38
arbitrary units (AUs), d56 0.69±0.44 AU; PI3Kg/ group:
d0 1.22±0.26 AU, d56 0.77±0.22 AU) excluding the
possibility that differences in anti-MPO titers were respon-
sible for the protection from NCGN in the PI3Kg/ mice.
Furthermore, mice transplanted with WT BM showed
slightly higher circulating white blood counts and neutrophil
counts at d56, probably reflecting disease activity similar to
what is seen in patients with active ANCA vasculitis (Table 1).
Finally, both groups showed similar engraftment rates with
MPO-positive circulating neutrophils (data not shown).
These data establish that neutrophil PI3Kg is important for
NCGN induction by anti-MPO antibodies without affecting
BM engraftment, anti-MPO titers, or the deposition of
immunoglobulins and complement.
Glomerular neutrophil and macrophage influx was
diminished in PI3Kc/ Mice
To test whether PI3Kg has an important function in
leukocyte migration in vivo, we assessed glomerular neu-
trophil and monocyte/macrophage accumulation. The data
show a reduced neutrophil and monocyte/macrophage influx
in glomeruli from mice transplanted with PI3Kg/ BM
(Table 2). These findings indicate that PI3Kg is needed for
circulating leukocytes to accumulate in the glomeruli and
induce NCGN.
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Figure 1 |Myeloperoxidase (MPO)-deficient animals were
immunized with MPO, irradiated, and transplanted with bone
marrow (BM) cells from either wild-type (WT) or
phosphoinositide 3 kinase-c isoform (PI3Kc/) mice. Mice
were killed 8 weeks after BM transplantation and albuminuria (a),
as well as renal tissue was examined. WT BM-transplanted mice (b)
developed glomerular crescents and necrosis, whereas PI3Kg/
BM-transplanted mice (c) were protected. The extent of
glomerular crescents and necrosis were expressed as the mean
percentage of glomeruli with crescents and necrosis (d).
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Pharmacological PI3Kc inhibition blocks ANCA-induced Akt
phosphorylation in primed neutrophils
We showed earlier that ANCA stimulation results in a second
Akt phosphorylation wave in cytokine-primed neutrophils.15
We used two priming cytokines that differ in their ability to
induce PI3Kg. Tumor necrosis factor-a (TNFa) acts through
G-protein-coupled-receptor-mediated PI3Kg activation
and granulocyte macrophage colony-stimulating factor
(GM-CSF) activates RTK that does not induce PI3Kg.34–36
Accordingly, we observed significant inhibition of TNFa-
induced Akt phosphorylation with 10 mmol/l LY294002 as a
nonspecific PI3K inhibitor and with 0.5 mmol/l AS605240 as a
PI3Kg-specific inhibitor (Figure 2a). In contrast, LY294002
prevented Akt phosphorylation in GM-CSF-treated neutro-
phils whereas AS605240 did not. Western blot experiments
indicate that 0.5 mmol/l AS605240 does not block p38 and
extracellular signal-regulated kinase (ERK) phosphorylation
underscoring the specificity for PI3Kg inhibition (Figure 2b
and c). Stimulation with human ANCA after cytokine
priming caused a second strong Akt phosphorylation wave
that was not observed with control IgG. Pretreatment with
either LY294002 or AS605240 blocked Akt phosphorylation
in both GM-CSF- and TNFa-primed neutrophils subse-
quently activated by human ANCA IgG (Figure 3). These
findings show that ANCA-activated PI3K and that PI3Kg
isoform inhibition blocked Akt phosphorylation.
PI3Kc inhibition blocks ANCA-induced reactive oxygen
species generation in neutrophils
We next tested whether PI3Kg inhibition prevents respiratory
burst by ANCA. We first titrated a dose-response study where
cells were preincubated over an AS605240 range from
2 106 to 1 109 mol/l for 30 min followed by GM-CSF
priming and treatment with a monoclonal antibody (mAb)
to MPO (Figure 4a). On the basis of these data, neutrophils
were then pretreated with 0.5 mmol/l AS605240, primed with
GM-CSF or TNFa, and subsequently activated with human
ANCA IgG. Incubation of TNFa- or GM-CSF-primed
neutrophils with control IgG did not result in generation of
superoxide, whereas stimulation with MPO-ANCA IgG or
proteinase 3 (PR3)-ANCA IgG induced a strong respiratory
burst (Figure 4b). Pretreatment with LY294002 or with
AS605240 abrogated the ANCA-stimulated superoxide pro-
duction in either TNFa- or GM-CSF-primed neutrophils
(n¼ 4, Po0.05). The difference between both inhibitors was
not statistically significant. These data indicate that the PI3Kg
isoform is necessary for superoxide production by ANCA.
To investigate whether the reduction in superoxide
generation was merely a consequence of reduced ANCA
antigen expression, we performed flow cytometry experi-
ments. mPR3 expression of resting neutrophils was 47.9±4.9
mean fluorescence intensity that was upregulated with
2 ng/ml TNFa to 90.6±12.8 mean fluorescence intensity.
Treatment with 0.5 mmol/l AS605240 did not significantly
change the membrane expression. We observed 79.6±14.6
mean fluorescence intensity for TNFa-treated neutrophils
(n¼ 5, n.s.). Expectantly, treatment with 10 mmol/l SB202190
significantly abrogated TNFa-induced membrane PR3
expression as showed in parallel experiments (90.6±12.8
mean fluorescence intensity to 59.0±11.2; Po0.05; n¼ 5).
PI3Kc inhibition blocks ANCA-induced neutrophil
degranulation
We next tested whether PI3Kg inhibition abrogates neutro-
phil degranulation after stimulation with ANCA. Neutrophils
Table 1 | Peripheral blood cell analysis at the day of killing in
MPO-deficient mice transplanted with WT or PI3Kc/ BM
(Exp 1) and in VC-treated mice versus AS-treated mice (Exp 2)
(data are means±s.e.m.)
WBC
(Gpt/l)
HGB
(mg/dl)
Lym
(Gpt/l)
Mo
(Gpt/l)
Gra
(Gpt/l)
Exp 1
WT 17.2±10.0 13.4±1.1 9.7±5.2 1.9±1.9 5.6±3.9
PI3Kg/ 11.7±2.7 14.4±1.0 7.0±2.3 1.0±0.4 3.5±1.2
Exp 2
VC 5.9±1.2 12.3±0.5 2.7±0.7 0.3±0.1 2.4±0.6
AS 5.1±0.3 13.6±0.4 2.5±6.0 0.5±0.1 2.1±0.3
Abbreviations: AS, AS605240; BM, bone marrow; MPO, Gpt/l, giga-particles/liter; Gra,
granulocyte; HGB, hemoglobin; Lym, lymphocyte; Mo, monocyte; myeloperoxidase;
PI3K, phosphoinositol 3-kinase; VC, vehicle control; WBC, white blood cell count; WT,
wild type.
None of the comparisons showed significant differences.
Table 2 | Quantitated immunohistochemical microscopy for glomerular neutrophil and macrophage infiltration in
MPO-deficient mice transplanted with WT or PI3Kc/ BM (Exp 1) and in VC-treated mice versus AS-treated mice (Exp 2)
Neutrophils Macrophages
Group % Positive Glom Cells/+Glom Cells/Glom % Positive Glom Cells/+Glom Cells/Glom
Exp 1
WT 36.9±6.6* 1.4±0.1 0.5±0.1* 48.5±8.0* 1.4±0.1 0.7±0.1
PI3Kg/ 14.5±4.0 1.4±0.2 0.2±0.1 22.5±5.3 1.4±0.1 0.3±0.1
Exp 2
VC 35.2±11.0* 1.5±0.1 0.5±0.2 35.3±12.4 2.4±0.5 1.0±0.5
AS 7.2±2.0 1.3±0.2 0.1±0.0 12.1±2.4 1.3±0.2 0.2±0.1
Abbreviations: AS, AS605240; BM, bone marrow; MPO, myeloperoxidase; PI3K, phosphoinositol 3-kinase; VC, vehicle control; WT, wild type.
Numbers represent mean numbers±s.e.m. of positive glomeruli (% Positive Glom), mean numbers±s.e.m. of positive cells per positive glomeruli (Cells/þGlom),
mean numbers±s.e.m. of positive cells per glomerular cross section (Cells/þGlom).
*Po0.05.
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were pretreated with LY294002 or AS605240, followed by
priming with GM-CSF or TNFa, and subsequently activated
with human ANCA IgG. Degranulation of primary granules
was assayed by b-glucuronidase release. As shown in Figure
4c, degranulation of TNFa- and GM-CSF-primed neutro-
phils stimulated with ANCA IgG was significantly inhibited
by pretreatment with both PI3K inhibitors (n¼ 4, Po0.05).
These data show that activation of PI3Kg isoform by
ANCA IgG is essential for ANCA-induced neutrophil
degranulation.
PI3Kc inhibition blocks neutrophil migration
Glomerular neutrophil recruitment is a hallmark of ANCA-
induced glomerulonephritis. When we tested whether specific
inhibition of PI3Kg blocks migration toward GM-CSF, we
observed that neutrophil migration increased within the first
2 h reaching a plateau thereafter. Furthermore, a strong
reduction of migration occurred with both LY294002 and
AS605240 pretreatment (Figure 5). These data show that
PI3Kg controls neutrophil migration toward GM-CSF
in vitro. In a second set of experiments, the effect of
LY294002 and AS605240 on migration in the presence of
human ANCA IgG was assessed. Compared with control IgG,
GM-CSF-mediated migration was slightly decreased by MPO
and PR3 ANCA (n¼ 6, n.s.). However, LY294002 and
AS605240 showed a similar inhibitory effect on migration
in the presence of ANCA. For clarity, migration data after 2 h
are shown in Figure 5b.
PI3Kc inhibition does not influence spreading and adhesion
Other important neutrophil functions involved in the
multistep process of glomerular neutrophil influx in
ANCA-induced NCGN are adhesion to and spreading on
extracellular matrices. After 120 min, we observed an increase
in neutrophil adhesion to fibronectin with GM-CSF
treatment from 1.6±0.1 to 2.4±0.5 104 cells (Po0.05).
The GM-CSF effect was not inhibited by LY294002
(2.1±0.5 104) or AS605240 (2.3±0.7 104, n¼ 5, n.s.).
We then assessed whether mAb to PR3 or MPO further
increased GM-CSF-mediated adhesion. GM-CSF treatment
in the presence of isotype control for 120 min resulted in
2.3±0.3 104, with anti-MPO mAb in 2.6±1.2 104 and
with anti-PR3 mAb in 2.4±0.6 104 adherent cells. This
increase was small and not statistically significant (n¼ 5).
Furthermore, we found that GM-CSF treatment increased
neutrophil spreading on fibronectin (from 8±3 to 45%±12,
n¼ 5, Po0.05). The GM-CSF effect was not affected by
LY294002 (37%±14) or AS605240 (39%±14, n¼ 5, n.s.)
pretreatment. GM-CSF treatment in the presence of isotype
control resulted in 43%±12 with a variable effect by anti-
MPO mAb (57%±10) and anti-PR3 mAb (72%±8) that
was not statistically significant (n¼ 5, n.s.).
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Figure 2 |Western blot analysis for phospho-Akt, phospho-p38 mitogen-activated protein kinase, and phospho-ERK is shown.
Neutrophils were preincubated with 10mmol/l LY294002 (Ly), 0.5mmol/l AS605240 (AS), or dimethyl sulfoxide as a control (Bu). Cells were
subsequently primed with buffer (), tumor necrosis factor a (TNF), or granulocyte macrophage colony-stimulating factor (GM-CSF). After
10min, samples were harvested and phosphorylated Akt (pAkt, a), phosphorylated p38 mitogen-activated protein kinase (pP38, b), and
phosphorylated ERK (pERK, c) were determined by immunoblotting. A representative example of five independent experiments is shown.
Total Akt (tAkt) is shown as loading control. The corresponding densitometric analysis is given in (d).
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Oral AS605250 treatment protects animals from
ANCA-induced NCGN
We finally tested whether specific PI3Kg inhibition by orally
administered AS605250 provides a novel treatment option
for ANCA-induced NCGN. Immunized MPO-deficient mice
were irradiated and subsequently transplanted with WT BM
cells. At day 21 after transplantation treatment with oral
gavage twice daily containing 30 mg/kg body weight
AS605250 or vehicle control for the next 5 weeks was started.
We chose day 21 as a starting point to avoid interference with
BM engraftment. At this time point, we already found
engraftment with MPO-positive neutrophils in the circula-
tion and the beginning of urine abnormalities.
At 8 weeks after BM transplantation, all mice transplanted
with WT BM and treated with vehicle control showed
hematuria and proteinuria, whereas AS605240-treated mice
did not develop significant urine abnormalities. These results
were confirmed by a higher urinary albumin excretion in the
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mice treated with vehicle control in comparison to the
AS605240-treated group: 118.2±67.1 mg/ml in the control
mice compared with 32.8±15.1 mg/ml in the AS605240-
treated group. The difference did not reach statistically
significance.
All vehicle-control-treated mice developed NCGN on
histology (100% disease induction) whereas AS605240-
treated mice developed only weak glomerular abnormalities
(three of the six mice developed weak glomerular disease,
three did not develop any glomerular abnormalities). Mice in
the control group showed on average 15.6±3.9% crescents
and 6.0±1.5% necrosis, whereas mice in the AS605240 group
developed 1.4±0.6% crescents and 0.5±0.4% necrosis
(Po0.01 for both; Figure 6). Both groups showed similar
anti-MPO titers by enzyme-linked immunosorbent assay
(vehicle-control group: d0 1.25±0.41 AU, d56 1.10±0.64
AU; AS group: d0 1.39±0.52 AU, d56 0.99±0.83 AU),
similar engraftment with MPO-positive cells (data not
shown), and no difference in blood cell counts. These data
establish that AS605240 did not exert toxic effects that
interfered with BM engraftment (Table 1).
Glomerular neutrophil and macrophage influx was reduced
by AS605240 treatment
The glomerular neutrophil and macrophage accumulation in
anti-MPO NCGN was diminished in mice treated with
AS605240 as shown in Table 2, indicating that the blockade
of PI3Kg reduces in vivo glomerular neutrophil and
monocyte/macrophage accumulation.
DISCUSSION
We used in vivo models to show that PI3Kg controls
neutrophil functions that participate in ANCA-induced
glomerular damage. Our data suggest PI3Kg inhibition is a
new therapeutic approach in ANCA vasculitis. ANCAs induce
NCGN that resembles the human disease in several animal
models.8,33,37 Glomerular neutrophil influx is a hallmark of
ANCA-induced NCGN and neutrophils are the main effector
cells.38 Several neutrophil functions that are thought to
participate in the process of glomerular injury are induced by
ANCA, including superoxide generation,3,7,39 degranula-
tion,3,19 and cell adhesion.9,40 Elucidation of intracellular
pathways controlling these effector functions will identify
novel treatment targets. The more detailed the functional
significance of these signal events is understood the more
specific treatment can be designed.
We evaluated the importance of PI3Kg in an in vivo
ANCA model. We selected two different approaches, namely,
primarily PI3Kg gene-deleted mice and thereafter, oral
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Figure 4 |We studied the inhibitory effect of LY294002 and
AS605240 on antineutrophil cytoplasmic autoantibody
(ANCA)-induced superoxide release and degranulation.
Neutrophils were incubated with increasing concentrations of
AS605240 for 30min followed by 15min priming with granulocyte
macrophage colony-stimulating factor (GM-CSF) and subsequent
treatment with a monoclonal antibody (mAb) to myeloperoxidase
(MPO; n¼ 4, a). After preincubation with 10mmol/l LY294002,
0.5mmol/l AS605240, or dimethyl sulfoxide control, cells were
primed with either tumor necrosis factor a (TNFa) or GM-CSF
followed by activation with control IgG (Ctrl), MPO-ANCA, or
PR3-ANCA. Statistical analysis for the superoxide data is provided
in (b) and for degranulation in (c) (n¼ 4, *Po0.05; **Po0.01). In
each of the four independent experiments, preparations from two
patients with PR3-ANCA and two patients with MPO-ANCA were
tested. These data show that LY294002 and AS605240 block
ANCA-induced respiratory burst and degranulation.
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treatment with a specific PI3Kg inhibitor. The first approach
was undertaken to provide a proof-of-principle study to
firmly establish a function for the PI3Kg isoform in ANCA-
induced NCGN. We had an ideal option with our optimized
mouse model, because the model involves BM transplanta-
tion from WT mice into irradiated MPO-immunized
MPO-deficient mice.32,33 Transplantation of BM from
PI3Kg-deficient mice instead of WT BM almost completely
prevented NCGN in this neutrophil-dependent mouse model
of ANCA-induced disease. These experiments, together with
our in vitro data, strongly point toward an important
function for PI3Kg in neutrophils during ANCA-mediated
NCGN induction. Because transplantation of PI3Kg/ BM
deleted this isoform in all leukocytes, we cannot exclude an
additional function for PI3Kg in lymphocytes and mono-
cytes. However, we observed no reduction in BM engraft-
ment, anti-MPO titers, or circulating leukocyte numbers.
Our in vitro results show that ANCA-mediated activation
of respiratory burst and degranulation, as well cytokine-
initiated migration depends on the PI3Kg pathway. Two
classes of PI3K have been described in human neutrophils,
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Figure 5 | The effect of LY294002 and AS605240 on neutrophil
migration is shown. Neutrophils were preincubated with
dimethyl sulfoxide (DMSO) control (Buffer), 10 mmol/l LY294002, or
0.5mmol/l AS605240 and loaded in the upper well of a transwell
device. The percentage of neutrophils migrated toward
granulocyte macrophage colony-stimulating factor (GM-CSF) was
quantified by the myeloperoxidase (MPO) assay over a time
period of 4 h (n¼ 5, *Po0.05, a). In (b) neutrophils were
preincubated with DMSO control, 10 mmol/l LY294002, or
0.5mmol/l AS605240 for 30min. Control IgG, MPO-antineutrophil
cytoplasmic autoantibodies (ANCA), or PR3-ANCA were added
and samples were loaded into the upper well of the chamber. The
percentage of migrated cells responding to GM-CSF at 2 h is
depicted (n¼ 6, *Po0.05, **Po0.01). These data show that
LY294002 and AS605240 block cytokine-induced neutrophil
migration in the absence and presence of ANCA.
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Figure 6 |Myeloperoxidase (MPO)-deficient animals were
immunized with MPO, irradiated, and transplanted with
wild-type (WT) bone marrow (BM) cells. Mice were orally
treated with AS605240 or vehicle control from day 21 after
transplant for 5 weeks. Mice were killed 8 weeks after BM
transplantation and albuminuria (a) as well as renal tissue was
examined. WT BM-transplanted mice treated with vehicle control
(b) developed glomerular crescents and necrosis, whereas
AS605240-treated mice (c) were protected. The extent of
glomerular crescents and extent of necrosis were expressed as
the mean percentage of glomeruli with crescents or necrosis
(d; **Po0.01.).
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the phosphotyrosine-associated class IA p85/p110 isoform
and the G-protein-activated class IB p101/p110g isoform. We
used two different cytokine primers in our in vitro
experiments, TNFa as PI3Kg-dependent primer and GM-
CSF as PI3Kg-independent primer, and showed that ANCA
IgG itself activate PI3Kg. In these studies, we used the PI3Kg
inhibitor AS605240, as described previously.28,31 We sub-
stantiate and extend previous findings that ANCA activation
of neutrophils involves the PI3K pathway.13,15,41 Ben-Smith
et al.13 showed convincingly that ANCAs activate the PI3Kg
isoform. To our knowledge, our study is the first to show that
specific inhibition of the PI3Kg isoform blocks ANCA-
stimulated responses in vitro. We selected 0.5 mmol/l
AS605240, as based on our in vitro dose-response and
specificity studies, and observed an approximately 50%
inhibition of superoxide generation and in almost complete
inhibition of degranulation. Conceivably, PI3Kg participates
more in the degranulation response compared with respira-
tory burst. In addition, both in the absence and presence of
ANCA, we observed a strong decrease in neutrophil
migration toward a chemotactic gradient of GM-CSF
when PI3Kg was blocked. These data are supported by
published studies in PI3Kg/ mice whose neutrophils had
impaired chemotactic response toward IL-8, fMLP, C5a,
and MIP-1a in vitro and attenuated recruitment to the
peritoneal cavity.24–26,42
We recently showed involvement of C5a and the
neutrophil C5a receptor in ANCA-induced NCGN in mice.32
We found that ANCA-induced neutrophil degranulation
results in C5a generation and that C5a through the
neutrophil C5a receptor accelerates ANCA-induced neutro-
phil activation. C5a is a strong chemoattractant and it was
shown by others that C5a-induced signaling and functions in
neutrophils, including migration, involves PI3Kg.43 Possibly,
the reduction in glomerular neutrophil and macrophage
influx that we observed in the PI3Kg-deficient group is, at
least in part, also a consequence of blocking C5a receptor
signaling through PI3Kg pathway. Our animal experiments
establish the significance of PI3Kg. However, transplantation
of PI3Kg-deficient BM is currently not a feasible option
in patients.
We pursued a second in vivo approach to modulate PI3Kg
by applying a highly specific PI3Kg-isoform inhibitor,
namely AS605240. AS605240 is a small molecule that was
successfully used intravenously to prevent disease in a mouse
model of lupus nephritis and orally in a mouse model of
arthritis.28,31 On the basis of these results, we selected the oral
administration route twice daily over 5 weeks, thereby
mimicking the human situation. Oral treatment with
AS605240 prevented ANCA-induced NCGN in our animal
model. The drug was started 21 days after BM transplanta-
tion and did not interfere with engraftment and anti-MPO
antibody production. At this early time point, the disease was
approximately 5 weeks away from its culmination. We could
envision such a situation at the beginning of a relapse.
Whether starting treatment at later time points, when the
disease is more active, has the same efficiency needs to be
tested in future studies.
The perspectives for the patients are the pivotal function
of PI3Kg in ANCA-mediated neutrophil functions and
thereby documented a potential drug target. We used PI3Kg
gene-deleted mice to prove that this PI3Kg isoform controls
ANCA-mediated NCGN. Finally, we showed that pharmaco-
logical PI3Kg blockade abrogates the disease in an animal
model. We believe that these findings may provide a novel
treatment option in patients with ANCA vasculitis.
MATERIALS AND METHODS
Materials
TNFa and GM-CSF were obtained from R&D Systems (Wiesbaden-
Nordenstadt, Germany). Phorbol-2-myristate-13-acetate and Ficoll-
Hypaque were from Sigma-Aldrich (Deisenhofen, Germany). HBSS,
phosphate-buffered saline, and Trypan blue were from Biochrom
(Berlin, Germany) and dextran was purchased from GE Healthcare
(Amsterdam, the Netherlands). LY294002 and SB202190 were from
Calbiochem (Schwalbach, Germany). The PR3 mAb 4A5 was from
Wieslab (Lund, Sweden), the anti-PR3 mAb (CLB12.8) from Hiss
(Freiburg, Germany) and the mAb to MPO was from Acris
(Hiddenhausen, Germany), phospho-specific antibodies to p38
mitogen-activated protein kinase, ERK, and Akt (S473) were
from Cell Signaling (Frankfurt, Germany). The horseradish
peroxidase-labeled donkey anti-rabbit IgG was from GE Healthcare.
Endotoxin-free reagents and plastic disposables were used in all
experiments.
Human neutrophils and human IgG
Neutrophils from healthy donors were isolated from heparinized
whole blood as described previously.11 Cell viability by Trypan blue
exclusion was found to be 499% in every experiment. Wright-
Giemsa staining revealed a neutrophil percentage 495%. Normal
IgG and ANCA-IgG were prepared from normal volunteers and
patients with active MPO and PR3-ANCA disease using a High-
Trap-protein-G column in an A¨kta-FPLC system (GE Healthcare).
Measurement of respiratory burst
Superoxide was measured using superoxide dismutase-inhibitable
reduction of ferricytochrome c.44 Cells (0.75 106) were preincu-
bated with 5 mg/ml cytochalasin B for 10 min and primed with
2 ng/ml TNFa or 20 ng/ml GM-CSF for 15 min before human
ANCA (125 mg/ml) were added. In some experiments, cells were
pretreated for 30 min on ice with 10 mmol/l LY294002, the indicated
AS605240 concentrations and dimethyl sulfoxide (DMSO) control,
respectively. Samples were incubated in 96-well plates at 371C for up
to 60 min, and the absorption of samples with and without 300 U/ml
superoxide dismutase was scanned repetitively at 550 nm using a
Microplate Autoreader (Molecular Devices, Munich, Germany).
Flow cytometry to assess PR3 surface expression
Flow cytometry was used to evaluate the PR3 membrane expression.
Cells were preincubated with the inhibitors or DMSO control for
30 min on ice, followed by treatment with 2 ng/ml TNFa or HBSS
control for 15 min at 371C. Thereafter, cells were washed and stained
with an mAb to PR3 (CLB12.8) or an isotype control followed by a
secondary fluorescein isothiocyanate-conjugated F(ab)2-fragment of
goat anti-mouse IgG. Flow cytometry was performed using an
FACScan, and 10,000 events per sample were collected.
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Neutrophil adhesion and spreading
A total of 96-well plates coated with (10mg/cm2) fibronectin were used.
Neutrophils (1 105) in 100ml HBSSþ þ were either left untreated or
were treated with 20 ng/ml GM-CSF. In some experiments, cells were
pretreated for 30 min on ice with 10mmol/l LY294002, the indicated
AS605240 concentrations and DMSO control, respectively. When
indicated, cells were treated with 10mg/ml isotype control or mAb to
PR3 and MPO, respectively. Adherent cells were estimated using the
MPO assay. Briefly, adherent cells were lysed in 100ml of 0.5% Triton-
X-100. Substrate (100ml; 2,20-azino-bis-3-ethylbenzthiazoline-6-sulfo-
nic acid; Sigma-Aldrich) was added and OD was read at 450 nm. OD
of the experimental sample was compared with a standard curve that
showed an excellent correlation between OD and cell number
(R2¼ 0.96). For estimation of cell spreading, nonadherent cells were
discarded and the percentage of spread cells was assessed. At least 100
cells of each sample were counted by two investigators using phase-
contrast microscopy. Cells that were phase dark, enlarged, and
irregular were considered to be spread.
Degranulation assay
Neutrophils (5 105) were preincubated with 5 mg/ml cytochalasin
B and primed in a 96-well microtiter plate for 15 min with 2 ng/ml
TNFa or 20 ng/ml GM-CSF. Stimulation was performed with
125mg/ml PR3-ANCA or MPO-ANCA or human control IgG for
up to 120 min. At 30-min intervals the cell-free supernatants were
collected and b-glucuronidase activity was assessed by the cleavage
of phenolphthalein glucuronic acid (Sigma-Aldrich). Each tube
contained 50 ml of a 0.01 mol/l solution phenolphthalein glucuronic
acid in 0.1 mol/l acetic buffer (pH 4.6) with 0.04% Triton X-100,
and was mixed with 50 ml of the cell-free supernatant. OD values
were measured at 405 nm. Nonstimulated neutrophils served as
baseline, whereas the total b-glucuronidase content was obtained by
incubation 5 105 neutrophils with 1% Triton X-100.
Transmigration assay
Migration was tested in fibronectin-coated transwells (3.0mmol/l,
6.5 mm from Corning, NY, USA). Neutrophils (1.5 106) in HBSSþ þ
were stimulated at 371C with 5 ng/ml GM-CSF to transmigrate to the
lower well. When indicated, cells were treated with 125mg/ml PR3-
ANCA, MPO-ANCA, and control IgG, respectively. For time-course
studies, the upper chamber of the transwell device was gently moved to
a new well in 60-min intervals. Transmigrated cells were quantified by
MPO assay as described previously.7
Western blot analysis of phosphorylated Akt, p38
mitogen-activated protein kinase, and ERK
Samples were incubated for 5 min at 951C in loading buffer
(250 mmol/l Tris-HCl (pH 6.8) with 4% sodium dodecyl sulfate,
20% glycerol, 0.01% bromophenol blue, 10% b-mercaptoethanol).
Protein (20 mg) was loaded, electrophoresed on a 10% sodium
dodecyl sulfate-polyacrylamide gel, and transferred to a nitrocellu-
lose membrane. The membrane was blocked and incubated
overnight with the indicated primary antibodies, followed by a
horseradish peroxidase-labeled secondary antibody. Densitometry
was performed with the Chemicapt 12.8 software using a Chemi-
smart 5000 scanner (Vilber Lourmat, Eberhardzell, Germany).
Preparation of (E)-5-((quinoxalin-6-yl)methylene)
thiazolidine-2,4-dione (AS605240)
Quinoxaline-6-carbaldehyde (1.04 g, 6.55 mmol, 1 equiv.; Invitro-
gen, Karlsruhe, Germany) and thiazolidine-2,4-dione (1.15 g,
9.82 mmol, 1.5 equiv.) were dried under vacuum with gentle
heating in a 100 ml two-neck round bottom flask. The flask was
equipped with a reflux condenser and all solids were dissolved in dry
toluene (40 ml). Piperidine (0.6 equiv.) and acetic acid (0.6 equiv.)
were added and the mixture was refluxed at an oil bath temperature
of 115–1201C for 16 h. After cooling the formed precipitate was
filtered off, washed with acetonitrile, water, and methanol and dried.
The product was recrystallized from methanol to yield pale-yellow
powder (m.p. 2991C (dec.), 0.95 g 57% yield): 1H-NMR (DMF-d7,
300 MHz) d¼ 7.98–8.08 (m, 2H), 8.18–8.25 (m, 2H), 8.28–8.35 (m,
1H), 9.44 (s, 1H); 13C-NMR (DMF-d7, 75 MHz) d¼ 124.52, 129.34,
129.59, 131.55, 131.59, 132.90, 141.63, 141.86, 148.25, 148.75,
167.61, 171.76. ESI-MS: m/z 258.1 (MþH)þ .
Mice
C57BL/6J (B6) mice breeding pairs were purchased from Jackson
Laboratories (Bar Harbor, ME, USA). Mice lacking MPO (MPO–/–
mice) were the sixth-generation progeny of a backcross into B6 mice
originally generated by Aratani et al.45 MPO–/– mice (8- to 10-week
old) were used for immunization. B6 WT mice and PI3Kg/ mice
(9- to 10-week old; generous gift from Professor J Penninger,
Research Institute of Molecular Pathology, Vienna, Austria) were
used as BM donors. Local authorities approved all animal
experiments, which followed American Physiologic Society guide-
lines for animal care.
Immunization of mice
The purification of mouse MPO and the immunization of MPO–/–
mice were performed as previously described.33 MPO–/– mice were
immunized intraperitoneally with 10 mg of MPO in complete
Freund’s adjuvant. Antibodies were monitored by anti-MPO
enzyme-linked immunosorbent assay. The presence of circulating
anti-MPO antibodies was confirmed in selected animals by indirect
immunofluorescence microscopy assay on murine neutrophils as
described.33
BM transplantation in mice
After immunization the MPO/ mice were kept at sterile housing
conditions with food and water ad libitum (sterile water with
trimethoprim and sulfadoxine, Borgal). One week after the last
immunization, mice were gamma-irradiated with 900 rad of whole-
body dose and reconstituted with BM from WT or PI3Kg/ mice of
the same genetic background. BM cells were harvested from femurs
and tibia, erythrocytes were lysed, and 1.5 107 BM cells were
intravenously injected. Engraftment was measured by histochem-
istry for MPO activity on peripheral blood smears. In the treatment
experiments at day 22 after BM transplantation, AS605240 or vehicle
control (0.5% carboxymethylcellulose/0.25% Tween-20) was admi-
nistered orally by gavage twice daily at a dose of 30 mg/kg body
weight until killing at week 8. At killing, blood cell counts were
carried out by a hematology analyzer (Scil Vet abc, Viernheim,
Germany).
Functional evaluation of renal injury
Mice were placed in metabolic cages one day before killing and urine
was collected for 12 h overnight. Urine was tested by dipstick (Roche
Diagnostics Corp., Indianapolis, IN, USA) for hematuria and
leukocyturia and proteinuria and the extent is expressed as the
mean on a scale of 0 (none) to 4 (severe). The albuminuria was
determined by an albumin-specific enzyme-linked immunosorbent
assay (CellTrend, Luckenwalde, Germany).
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Histological evaluation of renal injury
Kidney tissue was collected at the time of killing and fixed in 10%
formalin and embedded in paraffin using routine protocols. Coronal
sections of specimens (4mmol/l) were stained with hematoxylin and
eosin, periodic acid Schiff ’s and evaluated by light microscopy. The
extent of glomerular crescents and necrosis were expressed as the
mean percent of glomeruli with crescents and necrosis in each
animal. For immunofluorescence microscopy to detect glomerular
localization of immune determinants, 4 mmol/l frozen sections were
stained with fluoresceinated antibodies. The glomerular IgG
deposition was performed by staining using fluorescein isothiocya-
nate-conjugated goat anti-mouse IgG (Molecular Probes, Invitro-
gen, Carlsbad, CA, USA). Deposition of mouse complement C3,
IgG, IgM, IgA, and MPO was visualized with a fluorescein
isothiocyanate-conjugated goat anti-mouse C3, IgG, IgM, IgA, and
MPO (ICN/Cappel, Aurora, OH, USA). Immunofluorescence
microscopy staining of glomeruli was expressed as the mean
intensity of staining for IgG, IgM, IgA, C3, and MPO on a scale
of 0 to 4þ . Glomerular neutrophil and macrophage influx was
visualized using a neutrophil-specific mAb to GR-1 (BD Bioscience,
Heidelberg, Germany) and a specific mAb to CD68 (AbD Serotec,
Duesseldorf, Germany) as described earlier.33
Statistical analysis
Results are given as mean±s.e.m. Comparisons between two groups
were carried out using paired t-tests and between multiple groups
with one- or two-way analysis of variance as indicated. Specific
differences between multiple groups were then determined by use
of a Bonferroni post hoc test. Differences were considered significant
if Po0.05.
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